InfuSystem Q1 revenue misses estimates on contract restructuring

Infusystem Holdings

07/05/2026 11:40

Overview

U.S. healthcare service provider's preliminary Q1 revenue fell 3%, missing analyst expectations

Adjusted EPS for Q1 beat analyst expectations; net income also exceeded estimates

Revenue decline driven by strategic restructuring of major biomedical services contract

Outlook

InfuSystem reaffirms 2026 pro-forma net revenue growth guidance of 6% to 8%

Company continues to forecast 2026 Adjusted EBITDA margin in the mid to low 20%s

Guidance includes implementation expenses for upgraded ERP system launched in March 2026

Result Drivers

CONTRACT RESTRUCTURING - Revenue declined mainly due to the strategic restructuring of the GE Healthcare biomedical services contract, which reduced revenue but led to greater expense savings and improved margins

PATIENT SERVICES GROWTH - Patient Services revenue rose 6%, driven by higher treatment volumes in Oncology and Wound Care, with Wound Care revenue more than doubling year-over-year due to new compression therapy devices

DEVICE SOLUTIONS DECLINE - Device Solutions revenue fell 17% due to lower biomedical services revenue from the contract restructuring, reduced equipment rentals, and fewer equipment sales, partially offset by higher disposable medical supplies sales

Company press release: ID:nBw3tt3jFa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$33.68 mln
$34.35 mln (5 Analysts)
Q1 EPS
Beat
$0.05
$0.03 (5 Analysts)
Q1 Net Income
Beat
$1.02 mln
$914,000 (4 Analysts)
Q1 Operating Income
Miss
$1.59 mln
$1.65 mln (4 Analysts)
Q1 Pretax Profit
Beat
$1.42 mln
$1.39 mln (3 Analysts)
Q1 Gross Profit
$19.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for InfuSystem Holdings Inc is $15.00, about 47.9% above its May 6 closing price of $10.14

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)